BioCentury
ARTICLE | Company News

FDA approves Lilly's Verzenio as first-line endocrine therapy

February 27, 2018 12:08 AM UTC

Eli Lilly and Co. (NYSE:LLY) said FDA approved Verzenio abemaciclib as first-line endocrine therapy in combination with an aromatase inhibitor to treat hormone receptor-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women.

The approval was based on the Phase III MONARCH 3 trial (see BioCentury Extra, April 24, 2017)...